We dive into the PRAGUE-25 trial, examining why catheter ablation outperformed lifestyle modification plus antiarrhythmic drugs for atrial fibrillation in obese patients, yet both approaches yielded meaningful health boosts. Hollie and Austin unpack what these findings mean for patient care and how future therapies might shift the landscape.